Can I Take Saw Palmetto with Evenity (Romosozumab)?

What Romosozumab (Evenity) Is and Why Cardiovascular Risk Matters

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein made by osteocytes that normally suppresses bone formation. Blocking sclerostin simultaneously increases bone formation markers and decreases bone resorption markers, producing a dual anabolic and anti-catabolic effect that no other approved osteoporosis drug replicates. The FDA approved romosozumab in April 2019 for postmenopausal women with severe osteoporosis who are at high fracture risk or have failed other therapies [1].

The FDA Black-Box Cardiovascular Warning

Evenity carries a boxed warning for increased risk of myocardial infarction (MI), stroke, and cardiovascular death. This warning emerged from the ARCH trial (N=4,093), in which romosozumab 210 mg monthly produced a statistically significant higher rate of serious cardiovascular events compared to alendronate over 12 months: 2.5% versus 1.9%, a difference that reached P<0.05 [2]. The FDA mandates that Evenity should not be initiated in patients who have had an MI or stroke within the preceding year [1].

How Romosozumab Is Metabolized

Romosozumab is a large-molecule IgG2 monoclonal antibody. Like all therapeutic monoclonals, it is degraded by proteolytic catabolism rather than hepatic cytochrome P450 (CYP) enzymes. That distinction matters: most herb-drug interactions are CYP-mediated, so romosozumab sits largely outside that framework [3]. The absence of CYP involvement is why there is no pharmacokinetic interaction with saw palmetto.

What Saw Palmetto Does in the Body

Saw palmetto (Serenoa repens) is a berry extract used most often for benign prostatic hyperplasia (BPH) symptom relief, though it is also marketed for hair loss and hormonal balance. The two pharmacologically active mechanisms most relevant to this discussion are 5-alpha reductase (5-AR) inhibition and mild antiplatelet activity.

5-Alpha Reductase Inhibition

Saw palmetto inhibits both isoforms of 5-AR, reducing the conversion of testosterone to dihydrotestosterone (DHT). A randomized crossover trial by Marks et al. (N=44) found that saw palmetto 320 mg daily for six months reduced intraprostatic DHT by roughly 32% compared to placebo (P<0.05) [4]. This hormonal modulation does not directly affect bone metabolism pathways targeted by romosozumab, so no pharmacodynamic clash at the osteocyte level is expected.

Antiplatelet and Mild Anticoagulant Effects

Multiple published case reports describe excessive intraoperative or postoperative bleeding in patients taking saw palmetto, consistent with an antiplatelet mechanism. Cheema et al. Documented spontaneous bilateral subdural hematomas in a patient taking saw palmetto 320 mg daily who had no other identified bleeding risk [5]. The Natural Medicines database categorizes the saw palmetto, anticoagulant/antiplatelet interaction as "moderate" based on pharmacological plausibility and case-report evidence [6].

CYP Enzyme Effects

In vitro data show that saw palmetto extract mildly inhibits CYP3A4 and CYP2D6 at high concentrations, but in vivo studies in healthy volunteers have not demonstrated clinically significant CYP inhibition at standard doses of 160 to 320 mg daily [7]. Because romosozumab bypasses CYP metabolism entirely, this point is largely academic for this specific pairing.

The Core Interaction: Pharmacodynamic, Not Pharmacokinetic

The critical distinction for clinicians and patients is that the concern here is pharmacodynamic rather than pharmacokinetic. A pharmacokinetic interaction would mean one substance changes how the other is absorbed, distributed, metabolized, or eliminated. That does not appear to occur with this pair.

Cardiovascular Risk Stacking

Romosozumab already carries an independent cardiovascular signal. Saw palmetto, through its antiplatelet activity, may theoretically increase the risk of cardiovascular events or complicate management if a cardiovascular event occurs. The mechanism is not additive in a strict pharmacological sense because the two agents act on completely different targets, but the clinical outcome of interest (cardiovascular morbidity) could be worsened by simultaneous use [2][5].

Hormonal Cross-Talk Considerations

Severe osteoporosis in postmenopausal women is already a low-estrogen, low-androgen state. Saw palmetto's DHT-lowering effect adds another layer of androgen suppression. Androgens contribute modestly to bone mineral density (BMD) in women; the NHANES III dataset found that serum testosterone correlated positively with femoral neck BMD in women aged 50 and older (r = 0.18, P<0.001) [8]. Whether the degree of DHT reduction achievable with saw palmetto at standard doses translates to measurable BMD attenuation during a 12-month romosozumab course is unknown, but the theoretical direction of effect is unfavorable.

The HealthRX medical team uses a three-tier pharmacodynamic risk framework when evaluating supplements alongside Evenity:

Tier 1 (Avoid): Supplements with strong independent cardiovascular signals or known platelet suppression greater than aspirin 81 mg. Examples include high-dose fish oil (>3 g EPA+DHA), nattokinase, and ginkgo biloba.

Tier 2 (Caution, Monitor): Supplements with moderate antiplatelet activity or mild hormonal effects. Saw palmetto falls here. Continue only with prescriber awareness, baseline platelet function assessment, and blood pressure monitoring at each monthly injection visit.

Tier 3 (Likely Safe): Supplements with no cardiovascular or hemostatic pharmacology. Examples include vitamin D3, calcium citrate, magnesium glycinate, and collagen peptides.

Clinical Evidence Basis for Romosozumab's Efficacy and Risk Profile

Understanding why a prescriber accepts romosozumab's cardiovascular risk in the first place helps contextualize how much additional risk from supplements is tolerable.

FRAME Trial Fracture Reduction Data

The FRAME trial (N=7,180) randomized postmenopausal women with osteoporosis to romosozumab 210 mg monthly or placebo for 12 months, followed by denosumab in both groups. At 12 months, romosozumab reduced new vertebral fracture risk by 73% versus placebo (P<0.001) and nonvertebral fracture risk by 25% (P<0.001) [9]. This magnitude of benefit is the reason prescribers accept the boxed warning in appropriately selected patients.

ARCH Trial Head-to-Head Data

The ARCH trial compared romosozumab to alendronate in women with severe osteoporosis (T-score <minus 2.5 plus prior fracture). After 24 months (12 months romosozumab then 12 months alendronate versus 24 months alendronate), romosozumab reduced the risk of new vertebral fracture by 48% and nonvertebral fracture by 19% compared to alendronate [2]. The cardiovascular imbalance noted above came from this same trial.

What These Numbers Mean for Supplement Decisions

A patient with a 73% reduction in vertebral fracture risk has a strong clinical reason to complete her 12-month Evenity course. Any supplement that nudges cardiovascular risk upward, even modestly, deserves scrutiny. Saw palmetto's antiplatelet effect is mild. Stopping it for the 12-month injection window is a straightforward risk-reduction step for most patients.

Monitoring Parameters If You Are Already Taking Both

Some patients arrive at their first Evenity injection already using saw palmetto long-term for BPH or hair concerns. Stopping abruptly rarely causes withdrawal effects, but the decision to continue, taper, or stop should happen with prescriber input.

Baseline Assessments Before Starting Romosozumab

The Endocrine Society clinical practice guideline on osteoporosis in postmenopausal women recommends cardiovascular risk stratification before initiating any bone-active agent with a cardiovascular signal [10]. For patients also taking saw palmetto, add the following to standard baseline work:

• Complete blood count with platelet count
• Prothrombin time and aPTT if any history of easy bruising
• Fasting lipid panel (saw palmetto may modestly lower LDL in some studies)
• Blood pressure measured at rest, both arms

Monthly Injection Visit Monitoring

Evenity is administered once monthly for 12 consecutive months, always in a clinical setting. Each visit is an opportunity to ask about new cardiovascular symptoms (chest pain, shortness of breath, sudden weakness, vision changes) and any unusual bleeding or bruising. Document saw palmetto use in the medication reconciliation at every visit.

When to Stop Saw Palmetto

Stop saw palmetto immediately and contact your prescriber if you develop:

• Any chest pain or pressure
• Sudden neurological symptoms (facial droop, arm weakness, slurred speech)
• Unusual bruising without trauma
• Blood in urine or stool

These symptoms require urgent evaluation regardless of supplement use, but their presence while taking both agents should prompt immediate reconciliation of all medications and supplements.

Practical Guidance for Patients

Saw palmetto is not absolutely contraindicated with romosozumab. The interaction is not listed as a hard contraindication in the Evenity prescribing information, which focuses its drug-interaction section on agents with direct cardiovascular or renal effects [1]. The practical approach depends on why you are taking saw palmetto.

If You Take Saw Palmetto for BPH

BPH is primarily a condition of men, but some postmenopausal women use saw palmetto for urinary symptoms. If your urologist or primary care physician prescribed it for a documented indication, do not stop without their input. Instead, schedule a medication reconciliation visit that includes both your osteoporosis prescriber and the clinician managing your BPH. Evidence for saw palmetto's efficacy in BPH is itself mixed: the STEP trial (N=225) found no statistically significant difference between saw palmetto 160 mg twice daily and placebo on the American Urological Association Symptom Index at 12 months [11].

If You Take Saw Palmetto for Hair Loss

The evidence base for saw palmetto in androgenetic alopecia is limited to small trials. A 24-week randomized trial by Rossi et al. (N=100) found that saw palmetto 200 mg daily produced a 38% improvement in hair density versus 68% for finasteride 1 mg, suggesting a real but weaker biological effect [12]. Given that weaker efficacy, the risk-benefit calculation for continuing during a 12-month Evenity course likely favors a pause, especially in patients with any cardiovascular risk factors.

Timing and Dose Separation

Unlike oral drug combinations where separating doses by hours can reduce a pharmacokinetic interaction, dose separation does not apply here. Romosozumab is injected subcutaneously by a clinician. Saw palmetto is taken orally. The interaction is pharmacodynamic and systemic, so timing relative to each injection does not reduce the concern.

What the Guidelines Say About Supplements During Osteoporosis Treatment

No major osteoporosis guideline specifically addresses saw palmetto. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines recommend that patients undergoing pharmacological treatment for osteoporosis maintain adequate calcium (1,000 to 1,200 mg daily from diet plus supplements) and vitamin D (800 to 1,000 IU daily), but are silent on herbals [13]. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) similarly focuses supplement guidance on calcium and vitamin D [14].

The silence on herbals is not reassurance. It reflects a gap in guideline methodology rather than evidence of safety. The AACE guidelines do state: "Patients should inform their treating clinician of all supplements and over-the-counter medications before initiating pharmacological therapy" [13].

The absence of a named interaction does not equal absence of risk. Proactive disclosure to your care team is the safest path.

Key Takeaways for Clinicians

Prescribers managing patients on Evenity who also take saw palmetto should document the supplement at every visit and assess cardiovascular risk at baseline using a validated tool such as the ACC/AHA 10-year ASCVD risk calculator [15]. Patients with a 10-year ASCVD risk above 10% represent the subset in whom even mild additive pharmacodynamic contributors deserve the most attention.

For patients with low cardiovascular risk, the practical benefit of stopping saw palmetto during the 12-month romosozumab window is modest but real. For patients with established cardiovascular disease or prior MI/stroke (who should not be starting Evenity at all per the boxed warning), saw palmetto avoidance is straightforward.

Document the conversation. Note that the patient was counseled about the pharmacodynamic, not pharmacokinetic, nature of the concern, the lack of a known direct interaction in the prescribing information, and the rationale for either continuing under monitoring or pausing for 12 months. A single-sentence note in the chart protects both the patient and the prescribing team.

The FRAME trial's 73% vertebral fracture risk reduction at 12 months [9] is too large a benefit to compromise for a supplement with mixed efficacy data and a plausible, if mild, cardiovascular pharmacodynamic signal.